Ixabepilone in Treating Patients With Metastatic, Recurrent, or Unresectable Kidney Cancer

NCT00182702 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

37

Enrollment

NIH

Sponsor class

Conditions

Clear Cell Renal Cell Carcinoma
Recurrent Renal Cell Cancer
Stage III Renal Cell Cancer
Stage IV Renal Cell Cancer

Interventions

DRUG: ixabepilone
OTHER: laboratory biomarker analysis

Sponsor

National Cancer Institute (NCI)